Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-04-16
2003-06-03
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S468000
Reexamination Certificate
active
06573296
ABSTRACT:
BACKGROUND AND SUMMARY OF THE INVENTION
The botanical family Simaroubaceae includes numerous species distributed primarily in pantropical regions. These plant species have been the source of a large family of bitter terpenold substances collectively termed quassinoids. Like many plant alkaloids or naturally isolated plant extracts, quassinoids have been found to have diverse biologic activity, including anti-malarial, anti-insecticidal, anti-amoebicidal, anti-leukemic, and anti-viral activity.
The great majority of quassinoids are heavily oxygenated lactones that include the following twenty carbon skeleton,
conventionally termed picrasane, although eighteen, nineteen, and twenty-five carbon skeletons are also known. Many variant ring structures and sidechains, particularly at C-15, are known (See eg. Polonsky, “Quassinoid Bitter Principles II”, Fortschr.Chem.Org Naturst, Progress in the Chemistry of Organic Natural Products, 1985, 47, 221). The present invention includes both novel and synthetically derived quassinoid analogs, as well as novel uses for such synthetic quassinoids and previously identified and isolated natural quassinoids. In one aspect of the present invention, disclosed is a compound characterized by the formula
wherein R
1
represents hydrogen, oxygen, alkyl, alkenyl, acyl, aryl, halogen, sulfo, nitro, carboxyl, hydroxyl, hydroxyalkyl, alkoxy, or other water soluble sidechain, and Y is a sidechain comprising hydrogen, alkyl, hydroxyalkyl, carboxyl, aryl, alkenyl, cycloalkanes, cycloalkenes, glycosaccharides, water soluble sidechains, amino acid, peptide, and any of the foregoing attached at C-15 by an ether, ester, carbonyl, or glycosidic linkage.
In preferred embodiments, the sidechain Y Is represented by the formula
wherein R
2
, R
3
, and R
4
taken separately or together represent hydrogen, alkyl, hydroxyalkyl, carboxyl, aryl, alkenyl, cycloalkanes, cycloalkenes, glycine, glycosaccharides, water soluble sidechains, amino acids, peptide, and any of the foregoing attached to the central carbon by an ether, ester, carbonyl, or glycosidic linkage.
Specific embodiments of the present invention include those wherein R
2
is a methyl group, R
3
is a methyl group, and R
4
is a hydroxyl group, those wherein R
2
is a methyl group, R
3
is a methyl group, and R
4
is a hydroxyalkane, hydroxyalkene, glycyl, glycosaccharides, or water soluble sidechain, or those wherein R
2
is an ethyl group, R
3
is a hydroxyl group, and R
4
is an ethyl group. In addition, compounds wherein R
2
is a methyl group, R
3
is a methyl group, and R
4
is a hydroxymethyl group, or wherein R
2
is a methyl group, R
3
is a methyl group, and R
4
is a methyl group are included in the scope of the present invention.
Alternatively, the Y sidechain of Formula III above can be modified to support ring structures such as aryls or cycloalkanes. For example, R
2
and R
3
taken together can form a C
3
to C
8
membered carbon ring, and R
4
substituted with a hydroxymethyl group. More specifically, R
2
and R
3
can be taken together form a three membered cycloalkane, with R
4
being a hydroxymethyl group.
In still other embodiments, the sidechain Y can be represented as
wherein R
5
, R
6
, and R
7
taken separately or together represent hydrogen, alkyl, hydroxyalkyl, carboxyl, aryl, alkenyl, cycloalkanes, cycloalkenes, glycine, glycosaccharides, or water soluble sidechains, amino acids, peptide, and any of the foregoing attached to the terminal carbon by an ether, ester, carbonyl, or glycosidic linkage.
More specifically, embodiments of the present invention wherein R
5
is an isopropyl group, R
6
is an isopropyl group, and R
7
is a hydroxyl group; wherein R
5
and R
6
taken together comprise a double bonded carbon group, and R
7
is a methyl group; or wherein R
5
is a hydrogen, R
6
is a hydrogen, and R
7
is a carboxyl group are contemplated as within the scope of the present invention.
In addition, cyclic ring structures wherein R
5
and R
6
taken together form a C
3
to C
8
membered carbon ring, and R
7
further comprises hydrogen, alkyl, hydroxyalkyl, carboxyl, aryl, alkenyl, cycloalkanes, cycloalkenes, glycine, glycosaccharides, water soluble sidechains, amino acids, peptide, and any of the foregoing attached to the terminal R
7
carbon by an ether, ester, carbonyl, or glycosidic linkage are within the scope of the present invention. More specifically, those embodiments wherein R
5
and R
6
taken together form a four membered cycloalkane, and R
7
is a hydroxyl group; wherein R
5
and R
6
taken together form a five membered cycloalkane, and R
7
is a hydroxyl group; wherein R
5
and R
6
taken together form a six membered cycloalkane, and R
7
is a hydroxyl group; wherein R
5
and R
6
taken together form a seven membered cycloalkane, and R
7
is a hydroxyl group; wherein R
5
and R
6
taken together form a four membered cycloalkane, and R
7
comprises a group having the formula
are considered to be within the scope of this invention.
Still other embodiments of the present invention also include the compound of formula IV above, wherein R
5
and R
6
taken together comprise a double bonded carbon group, and together with R
7
form a five membered cycloalkene. Alternatively, the sidechain Y of the compound represented by Formula II can be represented as
wherein R
8
and R
9
taken separately or together represent hydrogen, alkyl, hydroxyalkyl, carboxyl, aryl, alkenyl, cycloalkanes, cycloalkenes, glycine, glycosaccharides, water soluble sidechains, amino acids, peptide, and any of the foregoing attached to the terminal carbon by an ether, ester, carbonyl, or glycosidic linkage. More specifically, those embodiments of the present invention wherein R
8
is a methyl group and R
9
is a methyl group; or wherein R
8
is an isopropyl group and R
9
is an isopropyl group are within the scope of the present invention.
Another aspect of the present invention is the use of the foregoing described synthetically derived quassinoids, or previously known, purified and isolated quassinoids, for the treatment in conjunction with suitable pharmaceutical carriers of neoplastic disorders such as solid tumors. For example, a chemotherapeutic composition for treatment of cancer can comprise a combination of a compound characterized by the formula
wherein R
1
represents hydrogen, oxygen, alkyl, alkenyl, acyl, aryl, halogen, sulfo, nitro, carboxyl, hydroxyl, hydroxyalkyl, alkoxy, or other water soluble sidechain, and Y is a sidechain comprising hydrogen, alkyl, hydroxyalkyl, carboxyl, aryl, alkenyl, cycloalkanes, cycloalkenes, water soluble sidechains, amino acids, peptide, and any of the foregoing attached to the terminal carbon by an ether, ester, carbonyl, or glycosidic linkage, and a pharmaceutically acceptable carrier therefor. As will be appreciated by those skilled in the art, the particular pharmaceutical carrier can be saline solution incorporating suitable stabilants, buffers, antimicrobial agents, antifungal agents, or other such additions as required for storage and delivery. In addition, the present invention contemplates lyophilized storage, with activation upon mixing, or any other storage technique known and utilized by those skilled in the pharmaceutical arts.
Still another aspect of the present invention is the use of the foregoing described synthetically derived quassinoids, or previously known, purified and isolated quassinoids, for treatment in conjunction with suitable pharmaceutical carriers of viral infections. Viral infections may include rhinoviruses, pseudorabies, or retroviral infections such as human immunodeficiency virus (HIV). Advantageously, certain compounds according to the present invention are believed to preferentially target virally infected cells, instead of acting against isolated viral particles.
As will be appreciated by those skilled in the art, the particular. pharmaceutical carrier for use in conjunction with the antiviral compounds of the present invention can be saline solution incorporating suitable stabilants, buffers, antimicrobial agents, ant
Corbett Thomas H.
Grieco Paul A.
Morre D. James
Valeriote Frederick A.
Advanced Research and Technology Institute, Inc.
Leydig , Voit & Mayer, Ltd.
Travers Russell
LandOfFree
Therapeutic quassinoid preparations with antineoplastic,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic quassinoid preparations with antineoplastic,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic quassinoid preparations with antineoplastic,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3132685